Protein / target
Nectin-4
Protein at a glance
Biological role
Cell adhesion mediator
Strongest disease association
Ectodermal dysplasia - syndactyly syndrome
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Seems to be involved in cell adhesion through trans-homophilic and -heterophilic interactions, the latter including specifically interactions with NECTIN1.
View complete UniProt function annotationHide complete annotation
Seems to be involved in cell adhesion through trans-homophilic and -heterophilic interactions, the latter including specifically interactions with NECTIN1. Does not act as receptor for alpha-herpesvirus entry into cells
Subcellular location
Domains and Gene Ontology detail (13)Hide
Domains & features
Gene Ontology
- Cadherens junction
- Cextracellular exosome
- Cplasma membrane
- Fcell adhesion mediator activity
- Fidentical protein binding
- Freceptor ligand activity
- Fvirus receptor activity
- Pheterophilic cell-cell adhesion
- Phomophilic cell-cell adhesion
- Pnegative regulation of natural killer cell mediated cytotoxicity
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Cell adhesion
- ·Seems to be involved in cell adhesion through trans-homophilic and -heterophilic interac…
- ·Cell junction, adherens junction
- ·cell adhesion mediator activity
- ·heterophilic cell-cell adhesion
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Broader indication categories (1)Hide
Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Nectin-4 binding agent
Indicated for Carcinoma, Transitional Cell, Urologic Neoplasms, Neoplasms
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene NECTIN4
Gene-level evidence surfaced through the gene NECTIN4that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
1 compounds recorded · 1 approved
View all recorded compounds (1)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Antibodies — Emerging
Other modalities — Strong
View underlying tractability evidence (5)Hide
Raw Open Targets tractability assessment buckets, by modality.
Safety-related annotations
Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Indication expanded
Indication expansion: ENFORTUMAB VEDOTIN (BLA761137)
- Indication expanded
Indication expansion: ENFORTUMAB VEDOTIN (BLA761137)
- Label change
Label change: ENFORTUMAB VEDOTIN (BLA761137)
- New publicationEnfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
- Indication expanded
Indication expansion: ENFORTUMAB VEDOTIN (BLA761137)
- Indication expanded
Indication expansion: ENFORTUMAB VEDOTIN (BLA761137)
- New publicationThe Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
- New publicationEV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
- New publicationEnfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
- Label change
Label change: ENFORTUMAB VEDOTIN (BLA761137)
- Indication expanded
Indication expansion: ENFORTUMAB VEDOTIN (BLA761137)
- Label change
Label change: ENFORTUMAB VEDOTIN (BLA761137)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.